Shanghai Kehua Bio-engineering News

Kehua Biotech (002022) 2020 Semi-Annual Report Review: Molecular Diagnostics Business Is Growing Rapidly, POLARIS Series Products Are Worth Looking Forward To

興業證券Aug 30, 2020 00:00

Kehua Biotech (002022): Kehua Biotech's regular business is expected to resume growth after being pressured by the pandemic in the short term

安信證券May 14, 2020 00:00

Kehua Biotech (002022): The largest shareholder changed hands and entered a new stage in the development of the company

興業證券May 12, 2020 00:00

Comment on Kehua Biology (002022) Annual report in 2019 and Quarterly report in 2020: new products with rapid growth in molecular diagnostic business are worth looking forward to.

興業證券May 6, 2020 00:00

Kehua Biotech (002022) Interim Review: Performance Meets Expectations “Product+Channel” Accelerates Deployment

中泰證券Aug 27, 2018 00:00

Kehua Biotech (002022) Interim Report Review: Channel Business Expansion Drives Steady Growth in Performance

中金公司Aug 27, 2018 00:00

Kehua Biology (002022) comments: epitaxial mergers and acquisitions continue to improve the layout of molecular diagnosis

東北證券May 16, 2018 00:00

Comment on the Quarterly report of Kehua Biology (002022): rapid revenue growth and simultaneous development of endogenous and epitaxial growth

興業證券May 6, 2018 00:00

Kehua Biology (002022) Quarterly report comments: Channel integration actively promote performance growth is expected to recover

東北證券May 2, 2018 00:00

Comment on the annual report of Kehua Biology (002022): performance gradually improves the overall layout of products + channels

興業證券Apr 27, 2018 00:00

科华生物(002022)年报点评：业绩逐渐改善 整合渠道加强新业务模式探索

中泰證券Apr 20, 2018 00:00

科华生物(002022)年报点评：产品完善+渠道整合 业绩增长值得期待

東北證券Apr 20, 2018 00:00

科华生物(002022)点评：股权激励公布 业绩增长可期

東北證券Feb 13, 2018 00:00

科华生物(002022)点评：四季度业绩环比恢复 股权激励出台

國金證券Feb 12, 2018 00:00

科华生物(002022)动态跟踪：业绩符合预期 “产品+渠道”共同成长

東方證券Feb 11, 2018 00:00

科华生物(002022)动态跟踪：“参股奥华+日立合作”将加强现有产品线

東方證券Dec 29, 2017 00:00

科华生物(002022)三季报点评：贵州中标执行影响当期利润 未来有望贡献业绩

國金證券Nov 6, 2017 00:00

科华生物(002022)三季报点评：加强渠道建设 持续推进“内生增长+外延扩张”战略

東方證券Nov 3, 2017 00:00

科华生物(002022)季报点评：渠道整合优化 业绩拐点可期

東北證券Oct 31, 2017 00:00

科华生物(002022)中报点评：渠道并购迈开步伐 与现有业务具备协同效应

國金證券Aug 31, 2017 00:00